Literature DB >> 3192177

Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis.

J G Kenna1, J Neuberger, R Williams.   

Abstract

Previous investigations have shown that antibodies in sera from patients with halothane hepatitis recognize neoantigens, expressed in livers of halothane-exposed rabbits and rats, which consist of a halothane metabolite bound covalently to specific microsomal proteins. These studies have suggested that the patients' antibodies may play a role in the pathogenesis of the hepatitis. In the present investigation, human liver biopsy samples were analyzed using an immunoblotting method to seek evidence for expression of halothane-induced neoantigens in humans. Sera from four patients with halothane hepatitis, which recognized halothane-induced rabbit liver neoantigens of 100, 76 and 57 kD, reacted strongly with antigens of very similar molecular weights that were expressed in livers from two patients who had died of cardiac failure following recent anesthesia with halothane. The antigens were not expressed in normal human liver or in livers from three patients who died of cardiac failure following anesthesia with agents other than halothane. The human antigens were not recognized by antibodies present in various control sera. Recognition of the 100- and 76-kD human antigens by the patients' antibodies was greatly reduced by absorption of sera with liver microsomes from halothane-exposed rabbits, but not by absorption of sera with control rabbit microsomes. These results indicate that humans exposed to halothane express liver neoantigens which are analogous to the halothane metabolite-protein neoantigens characterized previously in halothane-exposed animals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192177     DOI: 10.1002/hep.1840080627

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  Retrospective study of post-anesthetic mild liver disorder associated with inhalation anesthetics, halothane and enflurane.

Authors:  Y Sakaguchi; S Inaba; Y Umeki; S Takahashi; J Yoshitake; Y Hayashi; K Akazawa; Y Nose
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

Review 3.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 4.  Drug metabolism and hepatotoxicity.

Authors:  J M Tredger; M Davis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 5.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

Review 6.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

7.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. 5-7 April 1989, Bristol. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

8.  Hepatic necrosis associated with halothane anesthesia in an alpaca.

Authors:  S Groom; S Checkley; B Crawford
Journal:  Can Vet J       Date:  1995-01       Impact factor: 1.008

Review 9.  Acute hepatic failure: limitations of medical treatment and indications for liver transplantation.

Authors:  M Peters; K H Meyer zum Büschenfelde; G Gerken
Journal:  Clin Investig       Date:  1993-11

Review 10.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.